IBA's interim Q3 report shows mixed results

Sales are up more than 50% for the first nine months of 2008 for radiopharmaceutical firm Ion Beam Applications (IBA), but the bottom line is expected to take a hit.

In its interim third-quarter report, the Louvain-la-Neuve, Belgium, company said the advance in sales is due to internal growth and its June acquisition of Cisbio Bioassays of France. Cisbio's U.S headquarters is in Bedford, MA.

IBA also noted that profit is expected to decrease for the nine-month period, due to restructuring and costs related to integrating Cisbio.

Related Reading

IBA to develop PET market in South Korea, September 25, 2008

IBA adds MI order, September 24, 2008

IBA nets proton therapy order, September 23, 2008

IBA finalizes proton beam upgrade, August 28, 2008

IBA, NeuroSurvival Technologies partner, August 14, 2008

Copyright © 2008 AuntMinnie.com

Page 1 of 1234
Next Page